Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04327427
Other study ID # 2017-01889
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2019
Est. completion date May 31, 2021

Study information

Verified date March 2020
Source University of Zurich
Contact Christian E Oberkofler, MD
Phone 0041792961264
Email christian.oberkofler@usz.ch
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In the experimental setting inhibition of platelet activation was able to reduce immune-mediated necroinflammatory liver disease and consecutively hepatocellular carcinoma development. Therefore, antiplatelet therapy may not only have a preventive effect on hepatic artery patency but also on tumor recurrence.

So far and to the best of our knowledge, no study investigated the effect of antiplatelet therapy on hepatic arterial patency, tumor recurrence and graft survival after primary liver transplantation.


Description:

Outcome Analysis of antiplatelet therapy with Aspirin in Liver Transplantation

BACKGROUND Arterial complications after liver transplantation (LT) are still one of the most serious complications, which might result in liver necrosis, abscess formation, ischemic cholangiopathy, and eventually graft loss. The sequel of these adverse events has a negative impact on graft and patient survival and remains a life-threatening complication with a high mortality and retransplantation rate. Therefore, an uncompromised inflow of the hepatic artery is crucial to avoid any occlusion after LT.

In the literature, the incidence of hepatic artery thrombosis ranges between 2.5 and 10%. So far, the possibility of preventing hepatic artery thrombosis through specific pharmacological prophylaxis with antiplatelet agents (Aspirin) has been poorly investigated, which may be in part due to the impaired coagulative state at the time of transplantation and the early postoperative period. On the other hand, platelets, the chief effectors of vascular homeostasis, have been identified as important players in the pathogenesis of both acute and chronic liver diseases in animal models.

In the experimental setting inhibition of platelet activation was able to reduce immune-mediated necro-inflammatory liver disease and consecutively hepatocellular carcinoma development. Therefore, antiplatelet therapy may not only have a preventive effect on hepatic artery patency but also on tumor recurrence.

So far and to the best of our knowledge, no study investigated the effect of antiplatelet therapy on hepatic arterial patency, tumor recurrence and graft survival after primary liver transplantation.

STUDY OBJECTIVES The primary goal of this study is to conduct a multicentre cohort analysis to investigate whether antiplatelet therapy with Aspirin has an impact on hepatic arterial patency after primary liver transplantation.

Specific aim #1: To evaluate if antiplatelet therapy with Aspirin has a protective effect on arterial patency after primary LT.

Specific aim #2: To identify if antiplatelet therapy with Aspirin has a protective effect on acute cellular rejection.

Specific aim #3: To identify if antiplatelet therapy with Aspirin has protective effect on tumor recurrence (HCC).

Specific aim #4: To investigate whether antiplatelet therapy with Aspirin has a protective effect on graft survival.

STUDY DESIGN This will be a multicentre single cohort study including only cases of deceased donor primary liver transplantation. Primary endpoint is 30-day arterial patency in patients with or without antiplatelet therapy with Aspirin after liver transplantation. Secondary endpoints include postoperative complications, tumor recurrence, graft- and patient survival. The study protocol has received approval by the local ethics committee (2016-01889) as well as published here prior to data collection.

SETTING This multicentre cohort study will include several high-volume centres worldwide. Each participating centre requires a prospective database from that data can be extracted. All consecutive cases of deceased donor liver transplantation requiring from 1st of January 2013 until 31st of December 2015 are included allowing a minimum follow-up time of 24 months. Data collection at Aspirin4olt.org will be prospective, structured, anonymized, and encrypted.

PUBLICATION POLICY For upcoming publications, two authorships of the participating centres will be guaranteed as a group-authorship indexed in PubMed.

INSTITUTIONAL REVIEW POLICY / ETHICAL POLICY Each participating centre is responsible to contact their local ethics committee and receive approval for participation, if applicable. For example, this project is considered as an audit in some countries and thus there is no need for formal approval in the form of a protocol submission.

ELIGIBILITY CRITERIA

Inclusion criteria:

Adult Liver transplantation (age ≥18 years) Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD) Primary liver transplantation, whole graft Arterial anastomosis: end-to-end, back table reconstruction

Exclusion criteria:

Split liver and living donor liver transplantation Paediatric liver transplantation (recipient age <18 years) Arterial conduits Multivisceral transplantations Retransplantations

ESTIMATED SAMPLE SIZE Each centre should provide at least 30 cases that meet the inclusion criteria to allow adequate event rates for each outcome.

Statistical methods The primary and secondary endpoints will be compared with patient and operation characteristics with univariate analysis. ROC Curve analysis will be performed to dichotomize continuous variables. Multivariable analysis (binary logistic and Cox regression) will be performed to identify independent risk factors. Statistical analysis will be performed using R Studio version 1.0.44 (RStudio, Inc. GNU Affero General Public License v3, Boston, MA, 2016) with the graphical user interface rBiostatistics.com beta version (rBiostatistics.com, London, UK, 2017, GNU License).

Christian E. Oberkofler Philip C. Müller Dimitri A. Raptis Henrik Petrowsky On behalf of the Aspirin4olt.org team Swiss HPB Center, Department of Surgery and Transplantation, University Hospital Zurich, Switzerland


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date May 31, 2021
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult Liver transplantation(age =18 years)

- Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)

- Primary liver transplantation, whole graft

- Arterial anastomosis: end-to-end, back table reconstruction

Exclusion Criteria:

- Split liver and living donor liver transplantation

- Paediatric liver transplantation (recipient age <18 years)

- Arterial conduits

- Multivisceral transplantations

- Retransplantations

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Aspirin
Outcome Analysis of Aspirin in liver transplantation

Locations

Country Name City State
Switzerland Department of Visceral and Transplantation Surgery Zurich CH/Zürich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Aspirin and arterial patency We will look, if antiplatelet therapy with Aspirin has a protective effect on arterial patency after primary liver transplantation by looking at postoperative lab values and imaging, if they were perfromed. 2 years
Secondary Aspirin and cellular rejection We will analyze patients with and without postoperative cellular rejection and the intake of Aspirin. 2 years
Secondary Aspirin and tumor recurrence We will look at post transplant tumor recurrence and if the recurrence does correlate with Aspirin intake. 2 years
Secondary Aspirin and graft survival We will look at the postoperative graft survival and devide graft survival in the group of patients who were under Aspirin postoperative with those who did not take Aspirin postoperative; both groups will be then compared. 2 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05818644 - Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
Not yet recruiting NCT06041490 - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation Phase 2
Recruiting NCT04443322 - Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Completed NCT03165916 - Study to Compare the Incidence of Biliary Complications After Liver Transplantation N/A
Withdrawn NCT04216303 - Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
Recruiting NCT04506398 - Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
Not yet recruiting NCT05853484 - Home-based Bimodal Lifestyle Intervention in Patients With Liver Cirrhosis Awaiting Orthotopic Liver Transplantation N/A
Not yet recruiting NCT05036031 - Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
Recruiting NCT05065125 - Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlass™) for Post-liver Transplant Anastomotic Stricture
Recruiting NCT06060392 - Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus N/A
Enrolling by invitation NCT05195944 - Semaglutide vs Sitagliptin Phase 4
Completed NCT05255510 - Risk of Acute Kidney Injury in Living Liver Donor Surgery
Not yet recruiting NCT06048445 - Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Completed NCT04182256 - Magnetic Spiderman for Preparation of Liver Donation N/A
Recruiting NCT04477967 - Design and Implementation of the Pediatric Liver Transplantation Biobank
Recruiting NCT05109156 - Preoperative Sepsis Timeline, Profile and Its Association With Recipient Outcome Following Live Donor Liver Transplant
Recruiting NCT06124209 - Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial Phase 4
Recruiting NCT04054999 - Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients Phase 4